Understanding the regulatory pathways for medical device market entry in Japan
Japan does not always use the term "registration" in the same way as some other jurisdictions. For medical devices, the required pre-market procedure may include notification for certain low-risk devices, certification by a Registered Certification Body, or approval by the Ministry of Health, Labour and Welfare with PMDA review. Because the route depends on the product, overseas manufacturers should avoid assuming that an approval or classification in another country will directly determine the Japanese pathway.
Notification generally applies to certain low-risk medical devices, typically associated with Class I medical devices. Although the procedure is lighter than certification or approval, the product classification, Japanese nomenclature, labeling and marketing responsibilities must still be reviewed carefully.
Certification may apply to certain Class II or Class III medical devices when applicable certification standards exist. A Registered Certification Body reviews the product against the relevant standards. The manufacturer must prepare appropriate product information, technical documentation and quality-related information.
Approval is required for medical devices that do not fall under notification or certification pathways. PMDA conducts a scientific review, and the final marketing approval is granted by the Ministry of Health, Labour and Welfare. This may require careful consideration of product classification, intended use, performance data, biological safety, sterilization, clinical evaluation, QMS matters, and labeling.
The first practical step in Japan medical device registration is understanding how the product is classified in Japan. A product's pathway may change depending on Japanese nomenclature, risk class, intended use, duration and nature of body contact, materials, sterilization status, use with other medical devices, and novelty compared with existing approved or certified devices. Even if a product is already marketed in the US, EU, China, Korea or other regions, the Japanese classification and regulatory route must be assessed separately.
Medical device procedures in Japan generally require involvement of a Japan-based Marketing Authorization Holder or a designated local structure.
Foreign manufacturing sites may need to be registered for Japan. This should be reviewed early because manufacturing site information, roles and responsibilities may affect the regulatory timeline.
QMS-related requirements are an important part of market entry in Japan. Overseas manufacturers should review how existing ISO 13485 documentation aligns with Japanese expectations and product-specific requirements.
For some medical devices, clinical evaluation may be an important part of the approval strategy. The need for clinical data depends on the product type, intended use, risk profile and available evidence.
Overseas manufacturers often face delays because of issues such as assuming foreign approval automatically supports Japan approval, unclear Japanese classification, incomplete comparison with existing Japanese devices, lack of alignment between intended use and available data, late preparation of QMS or manufacturing site information, insufficient understanding of MAH/DMAH roles, translation without regulatory adaptation, and underestimating PMDA review questions. These challenges can often be reduced by reviewing the Japan regulatory pathway at an early stage.
Expert Japan regulatory affairs consulting for medical devices.
Clinical evaluation strategy and CER preparation support.
Specialized support for GI endoscopy and related devices.
Expert support for biliary stents, ERCP and EUS-BD devices.
MK Consulting provides regulatory consulting support for medical device registration in Japan, including pathway assessment, product classification review, PMDA consultation strategy, and support for overseas manufacturers entering the Japanese market.
Contact MK Consulting